Biohaven Ltd. (BHVN) is up 7.74 percent during Tuesday's trading, gaining $3.35 to trade at $41.60. The stock's rise follows the FDA's acceptance of Biohaven's New Drug Application or NDA for troriluzole, a treatment for spinocerebellar ataxia, and its designation for Priority Review.
BHVN is currently trading at $41.28, up from the previous close of $38.25 on the New York Stock Exchange. The stock has fluctuated between $38.89 and $42.68 during today's session. Trading volume stands at 1.03 million shares, surpassing the average volume of 961,191.
The stock remains within its 52-week range of $26.80 to $62.21, as investors react positively to the potential milestone for Biohaven.
If approved, troriluzole would be the first FDA-approved treatment for this rare neurodegenerative disease, with commercialization expected in 2025.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.